NKTR

Nektar Therapeutics

$61.27

2.03 (3.43%) Today

— up— down

Compare NKTR

Market Cap

$2.02B+7.9%

Revenue (TTM)

$55.80M-27.1%

Net Income (TTM)

$-222,980,210

EPS (TTM)

-6.60

Shares Out

33.79M

Open

$59.96

Previous Close

$59.24

Day Range

$58.91 – $62.40

52-Week Range

$33.40 – $109.00

Beta

1.37

Volume

509.46K

Avg Volume

988.04K

Analyst Rating

Buy

Exchange

NASDAQ NMS - GLOBAL MARKET

About NKTR

Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. The company developed the world's first inhalable non-injectable insulin, Exubera, which was awarded as the bronze award by Wall Street Journal for its technological breakthrough.